Head-To-Head Contrast: Curaleaf (OTCMKTS:CURLF) & Sanuwave Health (NASDAQ:SNWV)

Curaleaf (OTCMKTS:CURLF) and Sanuwave Health (NASDAQ:SNWV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Risk & Volatility

Curaleaf has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Sanuwave Health has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of Curaleaf shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 14.9% of Sanuwave Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Curaleaf and Sanuwave Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curaleaf	$1.27 billion	1.25	-$231.07 million	($0.30)	-7.75
Sanuwave Health	$44.05 million	3.29	$11.81 million	($0.16)	-105.25

Sanuwave Health has lower revenue, but higher earnings than Curaleaf. Sanuwave Health is trading at a lower price-to-earnings ratio than Curaleaf, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Curaleaf and Sanuwave Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	1	1	2	3.25
Sanuwave Health	1	1	1	1	2.50

Sanuwave Health has a consensus target price of $51.00, suggesting a potential upside of 202.85%. Given Sanuwave Health’s higher possible upside, analysts plainly believe Sanuwave Health is more favorable than Curaleaf.

Profitability

This table compares Curaleaf and Sanuwave Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-18.08%	-23.17%	-6.65%
Sanuwave Health	26.64%	-141.56%	34.53%

Summary

Sanuwave Health beats Curaleaf on 9 of the 14 factors compared between the two stocks.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

About Sanuwave Health

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.